Andere Sprachen Perspective Therapeutics, Inc.

Aktien

A0MQNM

US46489V1044

CATX

Verzögert Nyse Andere Börsenplätze 21:53:37 10.05.2024			% 5 Tage	% 1. Jan.
1.745 ^USD	-3.06%		-4.14%	+331.59%

09.05.	PERSPECTIVE THERAPEUTICS, INC. : Cantor Fitzgerald behält die Bewertung Kaufen bei	ZM
30.04.	Perspective Therapeutics, Inc. gibt die Auswahl des Prüfpräparats VMT-a-NET für die Behandlung bestimmter Patienten mit neuroendokrinen Tumoren durch die U.S. Food and Drug Administration bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Perspective Therapeutics to Participate at Upcoming May Investor Conferences	06.05.
Perspective Therapeutics to Participate at Upcoming May Investor Conferences	03.05.
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results	02.05.
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30.04.
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30.04.
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	30.04.
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18.04.
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18.04.
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	18.04.
Perspective Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K	16.04.
Perspective Therapeutics to Participate at Upcoming April Investor Conferences	08.04.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results	28.03.
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
North American Morning Briefing : Markets Steady -2-	26.03.
North American Morning Briefing : Stock Futures -2-	19.03.
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	18.03.
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	18.03.
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	18.03.
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024	11.03.
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	06.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Perspective Therapeutics, Inc.

Aktien

A0MQNM

US46489V1044

CATX

Andere Sprachen

Filter